ASXL1 and acute myeloid leukemia: There are several other somatic mutations that can be considered for MRD monitoring in AML, such as DNMT3A, NRAS, ASXL1, TET2, FLT3-ITD, FLT3-TKD, IDH1, IDH2, WT1, etc. A recent study evaluated the use of a newly developed double drop-off droplet dPCR (DDO-ddPCR) assay for mutation screening and AML disease monitoring using cell-free DNA [43].